Inozyme Pharma Inc (INZY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inozyme Pharma Inc (INZY) has a cash flow conversion efficiency ratio of -0.917x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.15 Million) by net assets ($31.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See INZY days of operational coverage to measure how many days the company can operate on defensive assets alone.
Inozyme Pharma Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Inozyme Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inozyme Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inozyme Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bharat Rasayan Limited
NSE:BHARATRAS
|
0.000x |
|
Tangshan Jidong Equipment Engineering Co Ltd
SHE:000856
|
-0.031x |
|
HUA YU LIEN Development Co Ltd
TW:1436
|
-0.040x |
|
Kenmare Resources PLC
IR:KMR
|
0.060x |
|
Lexinfintech Holdings Ltd
NASDAQ:LX
|
0.081x |
|
Imperial Brands PLC
LSE:IMB
|
-0.086x |
|
SEONGAN CO. Ltd
KO:011300
|
-0.019x |
|
TEMC Co. Ltd.
KQ:425040
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Inozyme Pharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Inozyme Pharma Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Inozyme Pharma Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.83 Million | $-91.91 Million | -1.589x | -215.92% |
| 2023-12-31 | $140.48 Million | $-70.67 Million | -0.503x | -3.12% |
| 2022-12-31 | $118.39 Million | $-57.76 Million | -0.488x | -10.71% |
| 2021-12-31 | $109.27 Million | $-48.15 Million | -0.441x | -93.68% |
| 2020-12-31 | $158.10 Million | $-35.97 Million | -0.228x | -140.18% |
| 2019-12-31 | $-33.22 Million | $-18.81 Million | 0.566x | -16.75% |
| 2018-12-31 | $-13.88 Million | $-9.44 Million | 0.680x | -- |
About Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney… Read more